Baseline platelet count and creatinine clearance rate predict the outcome of neutropenia-related invasive aspergillosis

Clinical Infectious Diseases

Volumn 54, Issue 12, 2012, Pages

  Nouér, Simone Aranha ^a,b   Nucci, Marcio ^a,b   Kumar, Naveen Sanath ^b   Grazziutti, Monica ^b   Restrepo, Alejandro ^b   Anaissie, Elias ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; BILIRUBIN; CREATININE; IMMUNOGLOBULIN; VORICONAZOLE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CD4 LYMPHOCYTE COUNT; CREATININE CLEARANCE; DISEASE COURSE; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT CODING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL TIME; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; CREATININE; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INVASIVE PULMONARY ASPERGILLOSIS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MULTIPLE MYELOMA; NEUTROPENIA; PLATELET COUNT; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84861486416     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis298     Document Type: Article

References (39)

1. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91:1068-75. (Pubitemid 44208634)
2. Ribrag V, Dreyfus F, Venot A, Leblong V, Lanore JJ, Varet B. Prognostic factors of invasive pulmonary aspergillosis in leukemic patients. Leuk Lymphoma 1993; 10:317-21. (Pubitemid 23256608)
3. Ribaud P, Chastang C, Latge JP, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28:322-30. (Pubitemid 29241222)
4. Yeghen T, Kibbler CC, Prentice HG, et al. Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution. Clin Infect Dis 2000; 31:859-68. (Pubitemid 32299339)
5. Subira M, Martino R, Franquet T, et al. Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors. Haematologica 2002; 87:528-34. (Pubitemid 34533280)
6. Cordonnier C, Ribaud P, Herbrecht R, et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006; 42:955-63.
7. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44:531-40. (Pubitemid 46233255)
8. Gallien S, Fournier S, Porcher R, et al. Therapeutic outcome and prognostic factors of invasive aspergillosis in an infectious disease department: a review of 34 cases. Infection 2008; 36:533-8.
9. Nivoix Y, Velten M, Letscher-Bru V, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47:1176-84.
10. Parody R, Martino R, Sanchez F, Subira M, Hidalgo A, Sierra J. Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: single-center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes. Am J Hematol 2009; 84:571-8.
11. Reuter S, Kern W, Zenz C, Kern P. Prognostic factors for invasive aspergillosis in patients with haematological malignancies. Scand J Infect Dis 2009; 41:483-90.
12. Baddley JW, Andes DR, Marr KA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010; 50:1559-67.
13. Neofytos D, Fishman JA, Horn D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010; 12:220-9.
14. Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010; 95:644-50.
15. Zhang P, Jiang EL, Yang DL, et al. Risk factors and prognosis of invasive fungal infections in allogeneic stem cell transplantation recipients: a single-institution experience. Transpl Infect Dis 2010; 12:316-21.
16. Ramos ER, Jiang Y, Hachem R, Kassis C, Kontoyiannis DP, Raad I. Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles. Oncologist 2011; 16:1049-60.
17. Mikulska M, Raiola AM, Bruno B, et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant 2009; 44:361-70.
18. Anaissie EJ. Trial design for mold-active agents: time to break the mold-aspergillosis in neutropenic adults. Clin Infect Dis 2007; 44: 1298-306. (Pubitemid 46717291)
19. Marr KA, Schlamm H, Rottinghaus ST, et al. A randomised, doubleblind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. LB 2812. 22nd European Congress of Clinical Microbiology and Infectious Diseases, London, 2012.
20. Maertens J, Van EJ, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002; 186:1297-306. (Pubitemid 35193008)
21. Nouer SA, Nucci M, Kumar NS, Grazziutti M, Barlogie B, Anaissie E. Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin Infect Dis 2011; 53:671-6.
22. Koo S, Bryar JM, Baden LR, Marty FM. Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol 2010; 48:1255-60.
23. Maertens J, Buve K, Theunissen K, et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 2009; 115:355-62.
24. Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008; 46:1412-22. (Pubitemid 351589942)
25. Woods G, Miceli MH, Grazziutti ML, Zhao W, Barlogie B, Anaissie E. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 2007; 110:830-4. (Pubitemid 47257661)
26. Nucci M, Nouer SA, Grazziutti M, Kumar NS, Barlogie B, Anaissie E. Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin Infect Dis 2010; 51: 1273-80.
27. de PB, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-21.
28. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47:674-83.
29. Miceli MH, Dong L, Grazziutti ML, et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant 2006; 37:857-64.
30. Ozkurt ZN, Yegin ZA, Suyani E, et al. Factors affecting stem cell mobilization for autologous hematopoietic stem cell transplantation. J Clin Apher 2010; 25:280-6.
31. Nieboer P, de Vries EG, Vellenga E, et al. Factors influencing haematological recovery following high-dose chemotherapy and peripheral stem-cell transplantation for haematological malignancies; 1-year analysis. Eur J Cancer 2004; 40:1199-207. (Pubitemid 38526339)
32. Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med 2007; 48:1767-76. (Pubitemid 350099320)
33. Israel VK, Jiang C, Muggia FM, et al. Intraperitoneal 5-fluoro-2'-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Cancer Chemother Pharmacol 1995; 37:32-8.
34. Perkhofer S, Kehrel BE, Dierich MP, et al. Human platelets attenuate Aspergillus species via granule-dependent mechanisms. J Infect Dis 2008; 198:1243-6.
35. Perkhofer S, Trappl K, Striessnig B, Nussbaumer W, Lass-Florl C. Platelets enhance activity of antimycotic substances against non-Aspergillus fumigatus Aspergillus species in vitro. Med Mycol 2011; 49:157-66.
36. Kergueris MF, Milpied N, Moreau P, Harousseau JL, Larousse C. Pharmacokinetics of high-dose melphalan in adults: influence of renal function. Anticancer Res 1994; 14:2379-82.
37. Cornwell GG III, Pajak TF, McIntyre OR, Kochwa S, Dosik H. Influence of renal failure on myelosuppressive effects of melphalan: Cancer and Leukemia Group B experience. Cancer Treat Rep 1982; 66:475-81. (Pubitemid 12084938)
38. Grazziutti ML, Dong L, Miceli MH, et al. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant 2006; 38:501-6. (Pubitemid 44445355)
39. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc 2010; 85:225-30.